Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease

Oskar Hansson, Sara Hall, Annika Öhrfelt, Henrik Zetterberg, Kaj Blennow, Lennart Minthon, Katarina Nägga, Elisabet Londos, Shiji Varghese, Nour Majbour, Abdulmonem Al-Hayani, Omar Ali El-Agnaf

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Introduction: The objective was to study whether α-synuclein oligomers are altered in the cerebrospinal fluid (CSF) of patients with dementia, including Parkinson disease with dementia (PDD), dementia with Lewy bodies (DLB), and Alzheimer disease (AD), compared with age-matched controls. Methods: In total, 247 CSF samples were assessed in this study, including 71 patients with DLB, 30 patients with PDD, 48 patients with AD, and 98 healthy age-matched controls. Both total and oligomeric α-synuclein levels were evaluated by using well-established immunoassays. Results: The levels of α-synuclein oligomers in the CSF were increased in patients with PDD compared with the controls (P < 0.05), but not in patients with DLB compared with controls. Interestingly, the levels of α-synuclein oligomers in the CSF were also significantly higher in patients with PDD (P < 0.01) and DLB (P < 0.05) compared with patients with AD. The levels of CSF α-synuclein oligomers and the ratio of oligomeric/total-α-synuclein could distinguish DLB or PDD patients from AD patients, with areas under the curves (AUCs) of 0.64 and 0.75, respectively. In addition, total-α-synuclein alone could distinguish DLB or PDD patients from AD patients, with an AUC of 0.80. Conclusions: The levels of α-synuclein oligomers were increased in the CSF from α-synucleinopathy patients with dementia compared with AD cases.

Original languageEnglish
Article number25
JournalAlzheimer's Research and Therapy
Volume6
Issue number1
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Synucleins
Lewy Body Disease
Parkinson Disease
Cerebrospinal Fluid
Dementia
Alzheimer Disease
Area Under Curve

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. / Hansson, Oskar; Hall, Sara; Öhrfelt, Annika; Zetterberg, Henrik; Blennow, Kaj; Minthon, Lennart; Nägga, Katarina; Londos, Elisabet; Varghese, Shiji; Majbour, Nour; Al-Hayani, Abdulmonem; Ali El-Agnaf, Omar.

In: Alzheimer's Research and Therapy, Vol. 6, No. 1, 25, 2014.

Research output: Contribution to journalArticle

Hansson, Oskar ; Hall, Sara ; Öhrfelt, Annika ; Zetterberg, Henrik ; Blennow, Kaj ; Minthon, Lennart ; Nägga, Katarina ; Londos, Elisabet ; Varghese, Shiji ; Majbour, Nour ; Al-Hayani, Abdulmonem ; Ali El-Agnaf, Omar. / Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. In: Alzheimer's Research and Therapy. 2014 ; Vol. 6, No. 1.
@article{0f2867f4959443c3bcef7a9b4c924b78,
title = "Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease",
abstract = "Introduction: The objective was to study whether α-synuclein oligomers are altered in the cerebrospinal fluid (CSF) of patients with dementia, including Parkinson disease with dementia (PDD), dementia with Lewy bodies (DLB), and Alzheimer disease (AD), compared with age-matched controls. Methods: In total, 247 CSF samples were assessed in this study, including 71 patients with DLB, 30 patients with PDD, 48 patients with AD, and 98 healthy age-matched controls. Both total and oligomeric α-synuclein levels were evaluated by using well-established immunoassays. Results: The levels of α-synuclein oligomers in the CSF were increased in patients with PDD compared with the controls (P < 0.05), but not in patients with DLB compared with controls. Interestingly, the levels of α-synuclein oligomers in the CSF were also significantly higher in patients with PDD (P < 0.01) and DLB (P < 0.05) compared with patients with AD. The levels of CSF α-synuclein oligomers and the ratio of oligomeric/total-α-synuclein could distinguish DLB or PDD patients from AD patients, with areas under the curves (AUCs) of 0.64 and 0.75, respectively. In addition, total-α-synuclein alone could distinguish DLB or PDD patients from AD patients, with an AUC of 0.80. Conclusions: The levels of α-synuclein oligomers were increased in the CSF from α-synucleinopathy patients with dementia compared with AD cases.",
author = "Oskar Hansson and Sara Hall and Annika {\"O}hrfelt and Henrik Zetterberg and Kaj Blennow and Lennart Minthon and Katarina N{\"a}gga and Elisabet Londos and Shiji Varghese and Nour Majbour and Abdulmonem Al-Hayani and {Ali El-Agnaf}, Omar",
year = "2014",
doi = "10.1186/alzrt255",
language = "English",
volume = "6",
journal = "Alzheimer's Research and Therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease

AU - Hansson, Oskar

AU - Hall, Sara

AU - Öhrfelt, Annika

AU - Zetterberg, Henrik

AU - Blennow, Kaj

AU - Minthon, Lennart

AU - Nägga, Katarina

AU - Londos, Elisabet

AU - Varghese, Shiji

AU - Majbour, Nour

AU - Al-Hayani, Abdulmonem

AU - Ali El-Agnaf, Omar

PY - 2014

Y1 - 2014

N2 - Introduction: The objective was to study whether α-synuclein oligomers are altered in the cerebrospinal fluid (CSF) of patients with dementia, including Parkinson disease with dementia (PDD), dementia with Lewy bodies (DLB), and Alzheimer disease (AD), compared with age-matched controls. Methods: In total, 247 CSF samples were assessed in this study, including 71 patients with DLB, 30 patients with PDD, 48 patients with AD, and 98 healthy age-matched controls. Both total and oligomeric α-synuclein levels were evaluated by using well-established immunoassays. Results: The levels of α-synuclein oligomers in the CSF were increased in patients with PDD compared with the controls (P < 0.05), but not in patients with DLB compared with controls. Interestingly, the levels of α-synuclein oligomers in the CSF were also significantly higher in patients with PDD (P < 0.01) and DLB (P < 0.05) compared with patients with AD. The levels of CSF α-synuclein oligomers and the ratio of oligomeric/total-α-synuclein could distinguish DLB or PDD patients from AD patients, with areas under the curves (AUCs) of 0.64 and 0.75, respectively. In addition, total-α-synuclein alone could distinguish DLB or PDD patients from AD patients, with an AUC of 0.80. Conclusions: The levels of α-synuclein oligomers were increased in the CSF from α-synucleinopathy patients with dementia compared with AD cases.

AB - Introduction: The objective was to study whether α-synuclein oligomers are altered in the cerebrospinal fluid (CSF) of patients with dementia, including Parkinson disease with dementia (PDD), dementia with Lewy bodies (DLB), and Alzheimer disease (AD), compared with age-matched controls. Methods: In total, 247 CSF samples were assessed in this study, including 71 patients with DLB, 30 patients with PDD, 48 patients with AD, and 98 healthy age-matched controls. Both total and oligomeric α-synuclein levels were evaluated by using well-established immunoassays. Results: The levels of α-synuclein oligomers in the CSF were increased in patients with PDD compared with the controls (P < 0.05), but not in patients with DLB compared with controls. Interestingly, the levels of α-synuclein oligomers in the CSF were also significantly higher in patients with PDD (P < 0.01) and DLB (P < 0.05) compared with patients with AD. The levels of CSF α-synuclein oligomers and the ratio of oligomeric/total-α-synuclein could distinguish DLB or PDD patients from AD patients, with areas under the curves (AUCs) of 0.64 and 0.75, respectively. In addition, total-α-synuclein alone could distinguish DLB or PDD patients from AD patients, with an AUC of 0.80. Conclusions: The levels of α-synuclein oligomers were increased in the CSF from α-synucleinopathy patients with dementia compared with AD cases.

UR - http://www.scopus.com/inward/record.url?scp=84989182833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989182833&partnerID=8YFLogxK

U2 - 10.1186/alzrt255

DO - 10.1186/alzrt255

M3 - Article

VL - 6

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

SN - 1758-9193

IS - 1

M1 - 25

ER -